Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
July 14, 2008
- Traditional Business Model Seeing the End Coming: Mr Makov
July 14, 2008
- OPINION
July 14, 2008
- Nihon Chouzai Settles Prices with All Wholesalers by End of June
July 14, 2008
- Treatment with Erbitux Requires KRAS Gene Testing to Predict Efficacy
July 14, 2008
- BUSINESS NEWS IN BRIEF
July 14, 2008
- Biologics Provide a New Approach to RA Treatment in Japan
July 14, 2008
- Avapro Leaps to Top Position in May: Rep Track Survey
July 14, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 14, 2008
- 70 Amlodipine Generics Listed from 34 Companies
July 14, 2008
- Initial Goals in Action Program for Generics Almost Met
July 14, 2008
- Pharmacists Explain Generics to Only 11% of Patients: Survey
July 14, 2008
- GENERICS NEWS IN BRIEF
July 14, 2008
- Armala May Outperform Sutent: ASCO 2008 Key Highlight Seminar
July 14, 2008
- Pfizer's Research Center Split Off to Create RaQualia
July 14, 2008
- 2008 Innovative DDS
July 14, 2008
- Prefilled Syringes Launched for Enbrel
July 14, 2008
- R&D NEWS IN BRIEF
July 14, 2008
- Takeda Completes US Business Consolidation by Merging TAP
July 14, 2008
- Takeda Files NDA for Panitumumab
July 14, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…